PharmaShots Weekly Snapshots (November 06–10, 2023)
This week PharmaShots’ news was all about the updates on clinical trials, regulatory, pharma, Animal Health and DigiHealth. Check out our full report below:
BioCryst Pharmaceuticals and Clearside Biomedical Sign a Licence Agreement for the Development of Avoralstat Treating Patients with Diabetic Macular Edoema
Read More: BioCryst Pharmaceuticals & Clearside Biomedical
Atara Biotherapeutics and Laboratoires Pierre Fabre Expand Their Collaboration Agreement to Continue Developing and Marketing Ebvallo Worldwide
Read More: Atara Biotherapeutics & Laboratoires Pierre Fabre
Biotheus Enters into a Collaboration Agreement with BioNTech to Develop and Commercialize PM8002 for the Treatment of Multiple Solid Tumor Indications
Read More: Biotheus & BioNTech
Jazz Pharmaceuticals and MD Anderson Cancer Centre Sign a 5-Year Research Collaboration Agreement to Investigate Zanidatamab in Solid Tumours
Read More: Jazz Pharmaceuticals
Dewpoint Therapeutics and Evotec Enter into a Strategic Partnership to Accelerate Dewpoint's Oncology Pipeline
Read More: Dewpoint Therapeutics & Evotec
Veracyte has Entered into a Multi-Year Partnership with Illumina to Improve its in vitro Diagnostic (IVD) Tests and Expand Global Access for Patients
Read More: Veracyte & Illumina
Eccogene and AstraZeneca Signed a Collaboration Agreement to Develop and Commercialize ECC5004 for Cardiometabolic Diseases
Read More: Eccogene & AstraZeneca
Century Therapeutics Enters into a Collaboration Agreement with FUJIFILM Cellular Dynamics to Develop and Commercialize iPSC-Derived Cell Therapies for Autoimmune and Inflammatory Diseases
Read More: Century Therapeutics & FUJIFILM Cellular Dynamics
The US FDA Designated Plus Therapeutics' Rhenium (186Re) Obisbemeda as an Orphan Drug to Treat Breast Cancer with Leptomeningeal Metastases
Read More: Plus Therapeutics
The US FDA Approves Cabaletta's IND Application for CABA-201 to Treat Generalised Myasthenia Gravis (gMG)
Read More: Cabaletta
Samsung Bioepis & Organon's sBLA for Hadlima (Biosimilar, adalimumab) to Treat Plaque Psoriasis was Approved for Review by the US FDA
Read More: Samsung Bioepis & Organon's sBLA
Recor Medical and Otsuka Medical Devices’ Paradise Ultrasound Renal Denervation System for Hypertension Received the US FDA’s Approval
Read More: Recor Medical & Otsuka Medical Devices
The US FDA has Approved Takeda's Fruzaqla to Treat Metastatic Colorectal Cancer
Read More: Takeda
The US FDA Approved Eli Lilly’s Zepbound (tirzepatide) as a Treatment for Obesity or Overweight
Read More: Eli Lilly
BMS Reports that the sBLA for Breyanzi (lisocabtagene maraleucel) was Accepted by the US FDA's for the Treatment of Small Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukaemia (CLL) with a Priority Review
Read More: BMS
The US FDA Designates Lyell Immunopharma's LYL845 as an Orphan Drug to Treat Melanoma
Read More: LyellImmunopharma
MaaT Pharma Reports on the First MaaT033 Patient Dosage in the P-IIb Trial for Patients with Blood Cancer
Read More: MaaT Pharma
TILT Biotherapeutics Reports Results of the P-I Trial Evaluating TILT-123 for the Treatment of Solid Tumors SITC 2023
Read More: TILT Biotherapeutics
Results for Eblasakimab in Atopic Dermatitis and Chronic Obstructive Pulmonary Disease (COPD) were Presented by ASLAN Pharmaceutical at the DDDS 2023
Read More: ASLAN Pharmaceutical
Results from Two Studies for 124I-Evuzamitide by Attralus were Published in the Journal of the American College of Cardiology
Read More: Attralus
Travere Therapeutics, Filspari, IgA Nephropathy, IgAN, Focal Segmental Glomerulosclerosis, FSGS, Clinical Trials, P-III, PROTECT, DUPLEX
Read More: Travere Therapeutics
Results of Portable Neuromodulation Stimulator (PoNS) Therapy for Patients with Traumatic Brain Injury (TBI) were Reported by Helius Medical Technologies
Read More: Helius Medical Technologies
Atara Biotherapeutics Reports Results from the P-II Trial Evaluating ATA188 in Patients with Non-Active Progressive Multiple Sclerosis
Read More: Atara Biotherapeutics
Amgen Presents Results from the P-IV (FOREMOST) Trial Investigating Otezla (apremilast) for Early Oligoarticular Psoriatic Arthritis
Read More: Amgen
Abbott Reports Diabetes Treatment Outcomes from a Real-World Study Evaluating its Healthy Food Rx Program
Read More: Abbott
AstraZeneca Highlights Imfinzi's P-III Trial Results for the Treatment of Hepatocellular Carcinoma
Read More: AstraZeneca
Ionis Pharmaceuticals Highlight Results of the P-II Trial for Donidalorsen as a Treatment for Type 1 and Type 2 Hereditary Angioedema
Read More: Ionis Pharmaceuticals
Antech Launches a New UK-Based Veterinary Diagnostics Facility
Read More: Antech
GE HealthCare Signs a Collaboration Agreement with Masimo to Combine Masimo SET Pulse Oximetry with the Portrait Mobile Platform
Read More: GE HealthCare & Masimo
Mainz Biomed Enters into a Collaboration Agreement with Liquid Biosciences to Develop AI Enables Screening Tests for Colorectal Cancer
Read More: Mainz Biomed & Liquid Biosciences
Related Post: PharmaShots Weekly Snapshots (October 30– November 03, 2023)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.